// App-Quantinova.ai

4095 : High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability

Researchers

Presenter

  • Sandra Lopez

Principal Investigators

  • Michael P. Rettig

  • Kathryn Trinkaus

  • Peter Westervelt

  • John F. DiPersio

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Arrhythmia

  • Venous thrombosis

  • Graft-versus-host disease

Biomarkers

  • Cluster of Differentiation 34

  • Granulocyte-macrophage-colony stimulating factor

  • Regulatory T cells

Drug/Treatment

  • Sargramostim

  • Plerixafor

  • GM-CSF

  • Filgrastim

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved